LOS ANGELES, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that members of its management team will participate in fireside chats and 1x1 meetings at the following investor conferences:
Visit link:
ACELYRIN, INC. to Participate in Upcoming Investor Conferences
First-in-human trial initiation in MS patients is imminent First-in-human trial initiation in MS patients is imminent
Continued here:
Abata Therapeutics Receives FDA Fast Track Designation for ABA-101 for the Treatment of Progressive Multiple Sclerosis
RESEARCH TRIANGLE PARK, N.C., Aug. 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
Read the original here:
BioCryst to Present at Upcoming Investor Conferences
PURCHASE, N.Y., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, today announced that results from the SEQUEL study of CT1812, the Company’s lead candidate for the treatment of Alzheimer’s disease, were published in The Journal of Prevention of Alzheimer's Disease. SEQUEL was a single-site study that measured brain wave patterns in 16 adults with mild-to-moderate Alzheimer’s disease following 29-days of treatment with CT1812 or placebo. In this study, CT1812-treated participants exhibited consistent trends of improvement across all prespecified electroencephalography (EEG) parameters with several reaching significance, including the change in relative theta power in the central region (p=0.006) of the brain and AEC-c* (p=0.034), which assesses the connectivity between brain regions.
Read the original post:
Cognition Therapeutics Publishes EEG Findings from Phase 2 SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease
BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.
Continued here:
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
PARAMUS, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary dermal technologies, is pleased to announce its successful scientific Advisory Board meeting held during the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. Led by Starton’s Scientific Board members and Chief Medical Officer, the meeting was attended by recognized experts and key opinion leaders in the field of oncology and yielded significant insights and outcomes that will shape the Company’s research and development efforts in Chronic Lymphocytic Leukemia (CLL) and Multiple Myeloma (MM).
Company announcement – No. 41 / 2024
Read this article:
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
WESTLAKE VILLAGE, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Excerpt from:
Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows:
The rest is here:
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced that a late-breaking abstract presenting the primary analysis of the IGNYTE clinical trial has been selected for oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024 being held September 13-17, 2024, in Barcelona.
Read the original:
Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for...